0001104659-23-089578.txt : 20230810 0001104659-23-089578.hdr.sgml : 20230810 20230810081233 ACCESSION NUMBER: 0001104659-23-089578 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaccitech plc CENTRAL INDEX KEY: 0001828185 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40367 FILM NUMBER: 231157273 BUSINESS ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF BUSINESS PHONE: 44 (0) 1865 818808 MAIL ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech Ltd DATE OF NAME CHANGE: 20201014 8-K 1 tm2323324d1_8k.htm FORM 8-K
0001828185 false 0001828185 2023-08-10 2023-08-10 0001828185 VACC:AmericanDepositarySharesMember 2023-08-10 2023-08-10 0001828185 us-gaap:CommonStockMember 2023-08-10 2023-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 10, 2023

 

VACCITECH PLC

(Exact name of registrant as specified in its charter)

 

England and Wales 001-40367 Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

Vaccitech plc

Unit 6-10, Zeus Building Rutherford Avenue,

Harwell, Didcot, OX11 0DF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44 (0) 1865 818 808

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade Symbol(s) Name of each exchange on which
registered
American Depositary Shares VACC The Nasdaq Global Market
Ordinary shares, nominal value £0.000025 per share*    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 10, 2023, Vaccitech plc (the “Company”) provided an update on its financial information and recent corporate developments in the quarter ended June 30, 2023. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release dated August 10, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vaccitech plc
     
Date: August 10, 2023 By: /s/ William Enright
    William Enright
    Chief Executive Officer

 

 

 EX-99.1 2 tm2323324d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

 

OXFORD, United Kingdom, August 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.

 

“In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL,” said Bill Enright, Vaccitech’s Chief Executive Officer. “Looking ahead, we remain steadfast in our focus on HBV and are eagerly anticipating interim data from our ongoing Phase 2 trials which we expect to announce by the end of the year. We have been able to extend our cash runway into the second quarter of 2025, demonstrating Vaccitech’s ethos of agility and efficiency across our broad portfolio of programs.”

 

Second Quarter 2023 and Recent Corporate Developments

 

Clinical developments

 

·In April 2023, at the 35th Annual International Papillomavirus Conference, the Company presented topline data from the HPV001 (NCT04607850) Phase 1b/2 clinical trial evaluating VTP-200 in women infected with human papillomavirus (HPV). Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200. VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related severe adverse events. While the placebo group showed no antigen-specific T cell responses as measured by IFNg ELISpot, 26 of 29 women receiving varying doses of VTP-200 showed a response. The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.

·In June 2023, at the 2023 European Association for the Study of the Liver (EASL) International Liver Congress™, the Company presented final Phase 2 HBV002 (NCT04778904) data showing that VTP-300, both as monotherapy and in combination with a single low dose of nivolumab (anti-PD-1 agent) at the time of the second dose, induced meaningful, durable reductions of hepatitis B surface antigen (HBsAg) and that reductions were most prominent in patients with lower baseline HBsAg. VTP-300 led to a decline in HBsAg in the majority of people infected with genotypes B and C viruses. In addition, VTP-300-induced T cells showed cross-reactivity to the core antigen from genotypes A to E in ELISpot assays using peripheral blood mononuclear cells from VTP-300-treated healthy subjects and genotype-specific peptides A-E.

·Also in June 2023, the Company announced dosing of the first patient in the PCA001 clinical trial evaluating its next generation product candidate, VTP-850, in prostate cancer (NCT05617040). PCA001 is a multi-center, Phase 1/2 trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen response (PSA), and T cell response of VTP-850 monotherapy in men with prostate cancer with rising PSA after definitive local therapy for their disease (i.e. biochemical recurrence).

 

 1 

 

 

Key operational updates

 

·In June 2023, the Company completed relocation of its U.S. team to a new, state-of-the-art laboratory and office facility in Germantown, Maryland.

·In July 2023, the Company announced the retirement of Dr. Margaret Marshall, Chief Medical Officer, effective immediately. In connection with her retirement, Dr. Marshall and the Company will enter into a consulting agreement.

 

Upcoming Milestones

 

·In the second half of 2023, the Company expects to:

 

oAnnounce interim efficacy data from HBV003 (NCT05343481), a Phase 2b clinical trial of VTP-300, that further evaluates its potential as a component of a functional cure for chronic Hepatitis B.

oAnnounce interim efficacy data from the Phase 2a clinical trial (ACTRN12622000317796) collaboration with Arbutus of VTP-300 in combination with Arbutus’ siRNA therapeutic candidate, AB-729 for chronic hepatitis B.

oSubmit an Investigational New Drug (IND) application for VTP-1000, the Company’s lead SNAPvax technology candidate, for the treatment of celiac disease.

 

Q2 2023 Financial Highlights

 

·Cash position: As of June 30, 2023, the Company had cash and cash equivalents of $173.0 million, compared to $191.3 million as of March 31, 2023. The net cash used in operating activities was $17.0 million, primarily resulting from our net loss of $23.8 million adjusted by share based compensation of $2.0 million, depreciation and amortization of $1.3 million, and changes in our operating assets and liabilities. $3.0 million was used for investing activities, primarily from capital expenditures related to leasehold improvements on our new facility in Germantown, Maryland, consisting of laboratories and office space. $0.1 million was provided by financing activities being the proceeds received from the issuance of ordinary shares represented by American Depositary Shares through the Company’s “at-the-market” sales agreement, net of issuance costs. Based on current research and development plans, we expect our cash runway to fund our operating expenses and capital expenditure requirements into the second quarter of 2025.

 

 2 

 

 

·Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023. Revenue was comprised of the Company’s share of royalties received by Oxford University Innovation (OUI) as a result of commercial sales of Vaxzevria® by AstraZeneca.

·Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials. VTP-300 HBV research and development expenses increased as a result of the Phase 2 HBV002 final data and the two ongoing phase 2b clinical trials. The research and development expenses related to SNAPvax candidates, VTP-1000/VTP-1100 Celiac/ HPV Cancer, increased due to IND-enabling studies. The quarter-on-quarter R&D expense per program is outlined in the following table.

 

   Three months
ended
June 30, 2023		   Three months
ended
March 30, 2023		   Change 
   $000   $000   $000 
Direct research and development expenses by program:               
VTP-200 HPV   1,837    1,338    499 
VTP-300 HBV   3,757    2,118    1,639 
VTP-600 NSCLC1   79    275    (196)
VTP-850 Prostate cancer   242    215    27 
VTP-1000/VTP-1100 Celiac/HPV Cancer   3,018    1,572    1,446 
Other and earlier stage programs   701    280    421 
Total direct research and development expenses   9,634    5,798    3,836 
Internal research and development expenses:               
Personnel-related (including share-based compensation)   3,388    3,601    (213)
Facility-related   202    371    (169)
Other internal costs   319    44    275 
Total internal research and development expenses   3,909    4,016    (107)
Total research and development expense   13,543    9,814    3,729 

 

1 The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK.

 

·General and administrative expenses: General and administrative expenses were $13.1 million in the second quarter of 2023, compared to $12.1 million in the first quarter of 2023. The increase was mainly attributable to the unrealized foreign exchange loss of $4.2 million in the second quarter of 2023, compared to $3.5 million in the first quarter of 2023.

·Net loss: For the second quarter of 2023, the Company generated a net loss attributable to its shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $18.2 million, or $0.48 per share on both basic and fully diluted bases in the first quarter of 2023.

 

 3 

 

 

About Vaccitech

 

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity. The Company stands apart through a proprietary, multi-platform approach that has shown the ability to induce higher magnitudes of T cells compared with other technologies. Vaccitech is uniquely positioned to address the needs of large, underserved patient populations through a diverse clinical-stage pipeline of investigational therapies targeting life-threatening diseases that pose significant public health risk and have limited treatment options. The Company’s lead product candidates include VTP-300, an immunotherapy candidate designed as a component of a potential functional cure for chronic hepatitis B viral (HBV) infection; VTP-200, a non-invasive, early-stage investigational treatment for persistent, high-risk human papillomavirus (HPV); VTP-850, a novel T cell investigational therapy for prostate cancer; and VTP-1000, a preclinical T cell therapeutic candidate designed to restore immune tolerance in celiac disease. Vaccitech has proven drug development and scientific expertise in the field of immunization, co-inventing a COVID-19 vaccine with the University of Oxford, which is now approved and exclusively licensed worldwide to AstraZeneca. For more information, visit www.vaccitech.co.uk.

 

Forward looking statement

 

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “would,” “aim,” “forward,” “expect,” “plan,” “intend,” “believe,” “potential,” “continue,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward looking statements include express or implied statements regarding the Company’s future expectations, plans and prospects, and include, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, and VTP-850, statements regarding the timing for the potential IND application for VTP-1000, statements regarding the presentation of interim data, including with respect to VTP-300, and statements regarding the Company’s capital, including its cash runway. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, approval of the Company’s product candidates, the Company’s ability to fund its operations, global economic uncertainty, including disruptions in the banking industry, and the impact that the COVID-19 pandemic may have on the Company’s clinical trials, preclinical studies and access to capital and other risks identified in the Company’s filings with the Securities and Exchange Commission (the SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

 4 

 

 

VACCITECH PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

(UNAUDITED)

 

   June 30,   December 31, 
   2023   2022 
ASSETS          
Current assets:          
Cash and cash equivalents  $173,030   $194,385 
Accounts receivable   —    323 
Accounts receivable - related parties   349    5,524 
Research and development incentives receivable   3,137    4,541 
Prepaid expenses and other current assets   8,261    8,268 
Total current assets   184,777    213,041 
Goodwill   12,209    12,209 
Property and equipment, net   13,741    7,957 
Intangible assets, net   26,688    28,269 
Right of use assets, net   7,707    7,753 
Other assets   1,006    976 
Total assets  $246,128   $270,205 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable  $2,429   $3,748 
Accrued expenses and other current liabilities   8,547    8,061 
Operating lease liability - current   1,135    433 
Total current liabilities   12,111    12,242 
Non-Current liabilities:          
Operating lease liability   11,044    8,340 
Contingent consideration   2,117    1,711 
Deferred tax liability, net   2,094    3,746 
Other non-current liabilities   1,300    965 
Total liabilities  $28,666   $27,004 
Commitments and contingencies (Note 14)          
Shareholders’ equity:          
Ordinary shares, £0.000025 nominal value; 38,524,059 shares authorized, issued and outstanding (December 31, 2022: authorized, issued and outstanding: 37,683,531)   1    1 
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2022: authorized, issued and outstanding: 63,443)   86    86 
Deferred B shares, £0.01 nominal value; nil shares authorized, issued and outstanding (December 31, 2022:authorized, issued and outstanding: 570,987)   —    8 
Deferred C shares, £0.000007 nominal value, nil shares authorized, issued and outstanding (December 31, 2022: authorized, issued and outstanding: 27,828,231)   —    01 
Additional paid-in capital   385,636    379,504 
Accumulated deficit   (145,225)   (103,243)
Accumulated other comprehensive loss – foreign currency translation adjustments   (23,289)   (33,460)
Total shareholders’ equity attributable to Vaccitech plc shareholders’   217,209    242,896 
Noncontrolling interest   253    305 
Total shareholders’ equity  $217,462   $243,201 
Total liabilities and shareholders’ equity  $246,128   $270,205 

 

1indicates amount less than thousand

 

 5 

 

 

VACCITECH PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

(UNAUDITED)

 

   Three months ended   Six months ended 
   June 30, 2023   June 30, 2022   June 30, 2023   June 30, 2022 
License revenue (1)  $334   $17,063   $802   $32,072 
Research grants and contracts   —    —    —    9 
Total revenue   334    17,063    802    32,081 
Operating expenses                    
Research and development   13,543    9,720    23,357    20,421 
General and administrative   13,128    (5,892)   25,266    (2,156)
Total operating expenses   26,671    3,828    48,623    18,265 
(Loss)/income from operations   (26,337)   13,235    (47,821)   13,816 
Other income (expense):                    
Interest income   522    669    2,110    752 
Interest expense   (14)   (7)   (14)   (8)
Research and development incentives   559    826    1,716    1,874 
Other income   310    51    310    51 
Total other (expense) income   1,377    1,539    4,122    2,669 
(Loss)/profit before income tax   (24,960)   14,774    (43,699)   16,485 
Tax benefit   1,136    915    1,652    1,778 
Net (loss)/income   (23,824)   15,689    (42,047)   18,263 
Net loss attributable to noncontrolling interest   22    4    65    26 
Net (loss)/income attributable to Vaccitech plc shareholders   (23,802)   15,693    (41,982)   18,289 
                     
Weighted-average ordinary shares outstanding, basic   38,407,672    37,202,600    38,211,625    37,196,843 
Weighted-average ordinary shares outstanding, diluted   38,407,672    38,174,426    38,211,625    38,260,579 
Net (loss)/income per share attributable to ordinary shareholders, basic  $(0.62)  $0.42   $(1.10)  $0.49 
Net (loss)/income per share attributable to ordinary shareholders, diluted  $(0.62)  $0.41   $(1.10)  $0.48 
                     
Net (loss)/income  $(23,824)  $15,689   $(42,047)  $18,263 
Other comprehensive gain/(loss) – foreign currency translation adjustments   5,604    (16,807)   10,184    (22,790)
Comprehensive loss   (18,220)   (1,118)   (31,863)   (4,527)
Comprehensive loss attributable to noncontrolling interest   15    34    52    71 
Comprehensive loss attributable to Vaccitech plc shareholders  $(18,205)  $(1,084)  $(31,811)  $(4,456)

 

(1)Includes license revenue from related parties for the three and six month periods ended June 30, 2023 of $0.3 million and $0.8 million, respectively and for the three and six month periods ended June 30, 2022 of $17.1 million and $32.1 million, respectively.

 

 6 

 

 

IR contacts:

Christopher M. Calabrese 

Managing Director 

LifeSci Advisors

+1 917-680-5608

ccalabrese@lifesciadvisors.com 

Kevin Gardner

Managing Director

LifeSci Advisors

+1 617-283-2856

kgardner@lifesciadvisors.com

 

Media contact:

Audra Friis

Sam Brown, Inc.

+1 917-519-9577

audrafriis@sambrown.com

 

Company contact:

Jonothan Blackbourn

IR & PR Manager

Vaccitech

IR@vaccitech.co.uk

 

 7 

 

 EX-101.SCH 3 vacc-20230810.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 vacc-20230810_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 vacc-20230810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] American Depositary Shares[Member] Common Stock [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 vacc-20230810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2323324d1_ex99-1img001.jpg GRAPHIC begin 644 tm2323324d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 10, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2023
Entity File Number 001-40367
Entity Registrant Name VACCITECH PLC
Entity Central Index Key 0001828185
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Vaccitech plc
Entity Address, Address Line Two Unit 6-10
Entity Address, Address Line Three Zeus Building Rutherford Avenue
Entity Address, City or Town Harwell, Didcot
Entity Address, Country GB
Entity Address, Postal Zip Code OX11 0DF
City Area Code +44 (0)
Local Phone Number 1865 818 808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
American Depositary Shares[Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares
Trading Symbol VACC
Security Exchange Name NASDAQ
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.000025 per share*
XML 9 tm2323324d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001828185 2023-08-10 2023-08-10 0001828185 VACC:AmericanDepositarySharesMember 2023-08-10 2023-08-10 0001828185 us-gaap:CommonStockMember 2023-08-10 2023-08-10 iso4217:USD shares iso4217:USD shares 0001828185 false 8-K 2023-08-10 VACCITECH PLC X0 001-40367 Vaccitech plc Unit 6-10 Zeus Building Rutherford Avenue Harwell, Didcot OX11 0DF GB +44 (0) 1865 818 808 false false false false American Depositary Shares VACC NASDAQ Ordinary shares, nominal value £0.000025 per share* true false 00-0000000 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 25 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vaccitech.co.uk/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323324d1_8k.htm tm2323324d1_ex99-1.htm vacc-20230810.xsd vacc-20230810_def.xml vacc-20230810_lab.xml vacc-20230810_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323324d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "vacc-20230810_def.xml" ] }, "inline": { "local": [ "tm2323324d1_8k.htm" ] }, "labelLink": { "local": [ "vacc-20230810_lab.xml" ] }, "presentationLink": { "local": [ "vacc-20230810_pre.xml" ] }, "schema": { "local": [ "vacc-20230810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 1, "memberStandard": 1, "nsprefix": "VACC", "nsuri": "http://vaccitech.co.uk/20230810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323324d1_8k.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vaccitech.co.uk/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323324d1_8k.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "VACC_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares[Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://vaccitech.co.uk/20230810", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-089578-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-089578-xbrl.zip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end